About

GluGene

Vision

TARGETing Gene Therapies
to Everybody

GluGene Therapeutics offers innovative AAV gene therapy products for incurable diseases by vector engineering and process engineering technologies.
The key platform technology described by TARGET (Transforming AAV by Revolutionary Glue and Evolution Technology) maximizes the therapeutic capacity of AAVs by novel proprietary strategies to address intrinsic problems of the viral vectors. GluGene’s technology unparallelly expands current therapeutic regimes by ‘3E’ advanced approaches: Enhancement of organ specificity, Evasion of neutralizing antibody, and Expansion of therapeutic payloads. Furthermore, collaborative spirit of GluGene team welcomes constructive co-work.

History

Picture

2014.04

The promotion of human neural stem cells adhesion using bioinspired poly(norepinephrine) nanoscale coating

Journal of Nanomaterials (2014)

Picture

2015.05

SpONGE: spontaneous organization of numerous-layer generation by electrospray

Angewandte Chemie (2015)

Picture

2016.07

PEGylation and HAylation via catechol: α-amine-specific reaction at N-terminus of peptides and proteins

Acta Biomaterialia (2016)

Picture

2017.08

Inverted quasi-spherical droplets on polydopamine-TiO2 substrates for enhancing gene delivery

Macromolecular Bioscience (2017)

Picture

2017.09

Functional polysaccharide sutures prepared by wet fusion of interfacial polyelectrolyte complexation fibers

Advanced Functional Materials (2017)

Picture

2021.01

Foundation of
GluGene Therapeutics Inc.

Picture

2021.10

Seed investment

Picture

2021.09

Pastable, Adhesive, Injectable, Nanofibrous, and Tunable (PAINT) Biphasic Hybrid Matrices as Versatile Therapeutic Carriers

ACS applied materials & interfaces (2021)

Picture

2022.09

Establishment of research center

Picture

2023.04

KDDF project involvement

Picture

2023.05

Distinguishing between DNA-Loaded Full and Empty Capsids of Adeno-Associated Virus with Atomic Force Microscopy imaging

Langmuir (2023)

Picture

2023.07

Certificate of Venture Business

Picture

2024.03

Enhancing the Production of Adeno-Associated Virus (AAV)2 and AAV9 with High Full Capsid Ratio in HEK293 Cells through Design-of-Experiment Optimization of Triple Plasmid Ratio

Biotechnology Journal (2024)

Leadership

Moon Sue Lee

CEO

Chief Executive Officer & Co-founder,
GluGene Therapeutics Inc.
Founder, InnoTherapy Inc. (KOSDAQ)
Director, NVC Partners
B.S./M.S./Ph.D., Department of Biological Sciences, KAIST
Strategic planning, Samsung (SAIT), CJ



Jae-Hyung Jang

CTO

Chief Technology Officer & Co-founder,
GluGene Therapeutics Inc.
Professor, Department of Chemical and Biomolecular Engineering, Yonsei University
Post-Doc., U.C. Berkeley
Ph.D., Department of Chemical and Biological Engineering, Northwestern University
B.S., Department of Chemical Engineering, Yonsei University
Chang Y Kim

Vice President

VP Business Development,
GluGene Therapeutics Inc.
President, InnoTherapy America Inc.

FDA & EU Approval, BD, Commercialization, InnoTherapy America
Int`I Biz, BD, Strategy,
CJ Pharma, CJ America


Terms of Use

Copyright ©2023 GluGene Therapeutics Inc. ALL RIGHTS RESERVED